Research
Hormonal
A higher percentage of patients receiving retatrutide achieved weight losses of ≥5%, 10%, 15%, and 20% compared to placebo.
Retatrutide may be particularly effective for patients aiming for significant weight loss.
StrongSupportsmedium confidence
It also led to a higher percentage of patients achieving weight losses of ≥5, 10, 15, and 20 %.
Why this rating
Based on systematic review of clinical trials.
Source
Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials
Saurav Misra et al. · Journal of Basic and Clinical Physiology and Pharmacology · 2025
DOI 10.1515/jbcpp-2025-0113
systematic_review · n=1082
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →